Answers are grounded in this paper and cite their sources.
Demonstrates delayed synovial drug clearance in joints, suggesting enhanced osteoarthritis treatment.
Formation of cationic adalimumab–DEAE-dextran nanocomplexes markedly reduces synovial drug clearance following intra-articular administration ex-vivo , potentially resulting in prolonged retention within the joint and improving the efficiency of antibody-mediated osteoarthritis treatment.
No takes yet. Share an insight, caveat, or question.
Pabsch et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: